• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Sunday, January 29, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

New data presented at ESGO showcases clinical relevance of SOPHiA DDM Dx HRD solution

Bioengineer by Bioengineer
November 3, 2022
in Cancer
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

BOSTON, United States and LAUSANNE, Switzerland – November 2, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, debuted new data at the European Society of Gynaecological Oncology (ESGO) Congress as part of a poster (#PA-065) presented by Prof. Alexandre Harlé of the Institut de Cancérologie de Lorraine, France. The results show an evaluation of Homologous Recombination (HRD) detection supported by a deep learning algorithm in a clinical cohort of ovarian cancer patients treated with a PARP inhibitor.* The new evaluation data show the clinical utility of the SOPHiA DDM™ Dx HRD Solution for accurate HRD testing.

ESGO 2022 Poster Presentation

Credit: NA

BOSTON, United States and LAUSANNE, Switzerland – November 2, 2022 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, debuted new data at the European Society of Gynaecological Oncology (ESGO) Congress as part of a poster (#PA-065) presented by Prof. Alexandre Harlé of the Institut de Cancérologie de Lorraine, France. The results show an evaluation of Homologous Recombination (HRD) detection supported by a deep learning algorithm in a clinical cohort of ovarian cancer patients treated with a PARP inhibitor.* The new evaluation data show the clinical utility of the SOPHiA DDM™ Dx HRD Solution for accurate HRD testing.

The deep learning-based solution expands identification possibilities for HRD-positive ovarian cancer patients that could potentially benefit from first-line maintenance therapy with PARP inhibitors. In a single workflow, the SOPHiA DDM™ Dx HRD Solution can evaluate the causes and the consequences of HRD, which is a complex biomarker with predictive value in ovarian cancer. Approximately half of all newly diagnosed patients with advanced ovarian cancer have HRD-positive tumors.

The clinical relevance of the SOPHiA DDM™ Dx HRD Solution presented at ESGO was evaluated in a multicenter study using a sub-set of ovarian cancer samples[1]. The results demonstrate that median progression-free survival (PFS) was improved in PARPi-treated patients with HRD-positive status as detected by the SOPHiA DDMTM Dx HRD Solution*. The information presented at ESGO can be found at this page.

The SOPHiA DDM™ Dx HRD Solution is CE-IVD certified, enabling it to inform diagnostic purposes in the European Union and other markets recognizing this certification.

SOPHiA GENETICS empowers medical institutions to implement a decentralized testing approach for ovarian cancer management. Rather than having to send tests to larger laboratories, they can simplify and expedite the process in-house, allowing them to retain ownership of the data analyzed, in a cost-effective, timely and reliable manner to potentially allow for better therapy decisions.

*Interim results based on retrospective correlation findings outside the context of a clinical trial

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.

 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 


[1] PAOLA-1 ClinicalTrials.gov number, NCT02477644. Ray-Coquard I, Pautier P, Pignata S, et al. N Engl J Med. 2019;381(25):2416-2428. 



Method of Research

News article

Share12Tweet8Share2ShareShareShare2

Related Posts

World-first guidelines created to help prevent heart complications in children during cancer treatment

World-first guidelines created to help prevent heart complications in children during cancer treatment

January 29, 2023
Automated MALDI-TOF MS based high-throughput screening workflow for in vitro enzyme assays

A new Assay screening method shows therapeutic promise for treating auto-immune disease

January 27, 2023

Louisiana Cancer Research Center appoints Associate Director of Administration

January 27, 2023

Afternoon chemotherapy proved to deliver more desirable results for female lymphoma patients

January 27, 2023

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    64 shares
    Share 26 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    58 shares
    Share 23 Tweet 15
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

World-first guidelines created to help prevent heart complications in children during cancer treatment

Simulations reproduce complex fluctuations in soft X-ray signal detected by satellites

Measles virus ‘cooperates’ with itself to cause fatal encephalitis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In